Razoxane structure
|
Common Name | Razoxane | ||
---|---|---|---|---|
CAS Number | 21416-67-1 | Molecular Weight | 268.26900 | |
Density | 1.333g/cm3 | Boiling Point | 531.5ºC at 760mmHg | |
Molecular Formula | C11H16N4O4 | Melting Point | 193ºC | |
MSDS | USA | Flash Point | 275.3ºC |
Use of RazoxaneRazoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1]. |
Name | 4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione) |
---|---|
Synonym | More Synonyms |
Description | Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1]. |
---|---|
Related Catalog | |
Target |
Topoisomerase II |
In Vitro | Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model. |
In Vivo | Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2]. Animal Model: Sprague-Dawley rats[2] Dosage: 30 mg/kg or 10 mg/kg per day Administration: Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation Result: Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. |
References |
Density | 1.333g/cm3 |
---|---|
Boiling Point | 531.5ºC at 760mmHg |
Melting Point | 193ºC |
Molecular Formula | C11H16N4O4 |
Molecular Weight | 268.26900 |
Flash Point | 275.3ºC |
Exact Mass | 268.11700 |
PSA | 98.82000 |
Vapour Pressure | 1.33E-13mmHg at 25°C |
Index of Refraction | 1.534 |
Storage condition | room temp |
Water Solubility | DMSO: soluble40mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
RIDADR | NONH for all modes of transport |
---|---|
RTECS | TL6389900 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
J. Med. Chem. 51 , 6740-51, (2008) The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ... |
|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicol. Mech. Methods 18 , 217-27, (2008) ABSTRACT Drug-induced phospholipidosis (PL) is a condition characterized by the accumulation of phospholipids and drug in lysosomes, and is found in a variety of tissue types. PL is frequently manifes... |
|
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
J. Clin. Oncol. 30(10) , 1042-9, (2012) Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identify... |
4,4'-propylenebis(piperazine-2,6-dione) |
4,4'-Propane-1,2-diyldipiperazine-2,6-dione |
4,4'-(1-Methylethylene)bis(2,6-piperazinedione) |
dl-1,2-bis(3,5-dioxopiperazin-1-yl)-propane |
Propyliminum |
RAZOXANUM |
1,2-bis(3,5-dioxopiperazin-1-yl)-propane |
(+)-1,2-bis(3,5-dioxopiperazinyl)propane |
(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane |
Razoxane |